Want to see GCTK full AI Analyst Report?
GCTK Stock Chart & Stats
$0.29
$0.01(4.36%)
At close: 4:00 PM EDT
$0.29
$0.01(4.36%)
Day’s Range― - ―
52-Week Range$0.25 - $14.14
Previous Close$0.3
Volume246.34K
Average Volume (3M)2.54M
Market Cap
$3.68M
Enterprise Value-$3.69M
Total Cash (Recent Filing)$3.93M
Total Debt (Recent Filing)$26.00K
Price to Earnings (P/E)―
Beta3.12
Next Earnings
Aug 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.31
Shares Outstanding7,719,121
10 Day Avg. Volume100,775
30 Day Avg. Volume2,541,249
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.23
Price to Sales (P/S)0.00
P/FCF Ratio-0.23
Enterprise Value/Market Cap-1.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit167.56
Enterprise Value/Ebitda0.22
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Minimal DebtThe company carries minimal formal debt, which reduces near-term solvency pressure from creditors and preserves flexibility to prioritize R&D and clinical programs. Low leverage is a durable structural strength that eases interest obligations and supports longer runway from equity or convertible financing rounds.
IDE Filing For Implantable CGMSubmitting an IDE marks a clear shift from preclinical work to clinical validation in the U.S., enabling the company to generate pivotal human data for regulatory approval. This advances a differentiated, long-duration implantable CGM strategy that could create durable competitive advantage in diabetes monitoring if clinical outcomes are favorable.
Secured $5.5M FinancingThe $5.5M financing package materially bolsters near-term liquidity, extending runway for clinical and development programs and signaling institutional investor support. While dilutive, the capital reduces immediate funding risk and enables continued progress on regulatory and product milestones critical to long-term value creation.
Bears Say
No Meaningful Revenue; Persistent Cash BurnThe company reports essentially no revenue while consuming substantial cash (~-$16M TTM), creating ongoing funding needs. Persistent cash burn without commercial receipts is a structural weakness that raises dilution risk, constrains strategic optionality, and makes long-term R&D plans dependent on external financings.
Negative Stockholders' EquityNegative equity reflects accumulated losses and erodes balance-sheet resilience, limiting ability to absorb setbacks or secure favorable financing. This structural impairment can hinder strategic partnerships, increase borrowing costs, and create covenant or listing challenges that materially affect long-term financial flexibility.
Nasdaq Deficiency Notices And Delisting RiskNasdaq deficiency notices for minimum bid price and equity thresholds create meaningful structural risk to listing status and liquidity. Potential delisting would reduce market access, deter institutional investors, and complicate future capital raises or commercialization partnerships, impairing the company's ability to execute its long-term strategy.
GlucoTrack News
GCTK FAQ
What was GlucoTrack’s price range in the past 12 months?
GlucoTrack lowest stock price was $0.25 and its highest was $14.14 in the past 12 months.
What is GlucoTrack’s market cap?
GlucoTrack’s market cap is $3.68M.
When is GlucoTrack’s upcoming earnings report date?
GlucoTrack’s upcoming earnings report date is Aug 13, 2026 which is in 4 days.
How were GlucoTrack’s earnings last quarter?
GlucoTrack released its earnings results on May 14, 2026. The company reported -$2.646 earnings per share for the quarter, missing the consensus estimate of N/A by -$2.646.
Is GlucoTrack overvalued?
According to Wall Street analysts GlucoTrack’s price is currently Overvalued.
Does GlucoTrack pay dividends?
GlucoTrack does not currently pay dividends.
What is GlucoTrack’s EPS estimate?
GlucoTrack’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does GlucoTrack have?
GlucoTrack has 7,719,121 shares outstanding.
What happened to GlucoTrack’s price movement after its last earnings report?
GlucoTrack reported an EPS of -$2.646 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.84%.
Which hedge fund is a major shareholder of GlucoTrack?
Currently, no hedge funds are holding shares in GCTK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
GlucoTrack
Based in Or Yehuda, Israel, GlucoTrack, Inc. is a medical technology company focused on innovating, developing, and bringing to market non-invasive glucose monitoring systems. Their primary offering, the GlucoTrack device, enables individuals with diabetes or pre-diabetes to painlessly check their blood glucose levels. This technology is available to customers both in Israel and across the globe. The company, founded in 2001, operated under the name Integrity Applications, Inc. until it officially rebranded to GlucoTrack, Inc. in November 2021.
Technical Analysis
Ownership Overview
0.15% Insiders
0.14% Mutual Funds
0.20% Other Institutional Investors
99.51% Public Companies and
Individual Investors